	US 12,214,001 B2
	Cancer therapy
Livija Deban, London (GB); and Hyam Levitsky, Seattle, WA (US)
Assigned to Prokarium Limited, London (GB)
Filed by PROKARIUM LIMITED, London (GB)
Filed on Dec. 6, 2022, as Appl. No. 18/076,133.
Application 18/076,133 is a continuation of application No. 17/344,065, filed on Jun. 10, 2021, granted, now 11,529,378.
Claims priority of provisional application 63/037,179, filed on Jun. 10, 2020.
Claims priority of application No. 20184698 (EP), filed on Jul. 8, 2020.
Prior Publication US 2023/0143897 A1, May 11, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/74 (2015.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01)

CPC A61K 35/74 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/4644 (2023.05); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61K 9/0053 (2013.01)]

20 Claims

1. A method of treating, reducing, inhibiting or controlling a neoplastic disease in a subject undergoing or intended to undergo a checkpoint inhibitor therapy, an adoptive cell therapy and/or an allogenic or autologous CAR-T therapy, comprising administering simultaneously, separately or sequentially a live attenuated Gram-negative bacterium, wherein the live attenuated Gram-negative bacterium is orally administered, subcutaneously administered, intradermally administered or intramuscularly administered, wherein said live attenuated Gram-negative bacterium is non-recombinant or does not comprise eukaryotic heterologous DNA encoding a therapeutic protein.